Cargando…
Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway
High serum lipopolysaccharide (LPS) activity in normoalbuminuric patients with type 1 diabetes (T1D) predicts the progression of diabetic nephropathy (DN), but the mechanisms behind this remain unclear. We observed that treatment of cultured human podocytes with sera from normoalbuminuric T1D patien...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669704/ https://www.ncbi.nlm.nih.gov/pubmed/25950482 http://dx.doi.org/10.1038/cddis.2015.125 |
_version_ | 1782404147456245760 |
---|---|
author | Saurus, P Kuusela, S Lehtonen, E Hyvönen, M E Ristola, M Fogarty, C L Tienari, J Lassenius, M I Forsblom, C Lehto, M Saleem, M A Groop, P-H Holthöfer, H Lehtonen, S |
author_facet | Saurus, P Kuusela, S Lehtonen, E Hyvönen, M E Ristola, M Fogarty, C L Tienari, J Lassenius, M I Forsblom, C Lehto, M Saleem, M A Groop, P-H Holthöfer, H Lehtonen, S |
author_sort | Saurus, P |
collection | PubMed |
description | High serum lipopolysaccharide (LPS) activity in normoalbuminuric patients with type 1 diabetes (T1D) predicts the progression of diabetic nephropathy (DN), but the mechanisms behind this remain unclear. We observed that treatment of cultured human podocytes with sera from normoalbuminuric T1D patients with high LPS activity downregulated 3-phosphoinositide-dependent kinase-1 (PDK1), an activator of the Akt cell survival pathway, and induced apoptosis. Knockdown of PDK1 in cultured human podocytes inhibited antiapoptotic Akt pathway, stimulated proapoptotic p38 MAPK pathway, and increased apoptosis demonstrating an antiapoptotic role for PDK1 in podocytes. Interestingly, PDK1 was downregulated in the glomeruli of diabetic rats and patients with type 2 diabetes before the onset of proteinuria, further suggesting that reduced expression of PDK1 associates with podocyte injury and development of DN. Treatment of podocytes in vitro and mice in vivo with LPS reduced PDK1 expression and induced apoptosis, which were prevented by inhibiting the Toll-like receptor (TLR) signaling pathway with the immunomodulatory agent GIT27. Our data show that LPS downregulates the cell survival factor PDK1 and induces podocyte apoptosis, and that blocking the TLR pathway with GIT27 may provide a non-nephrotoxic means to prevent the progression of DN. |
format | Online Article Text |
id | pubmed-4669704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46697042015-12-04 Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway Saurus, P Kuusela, S Lehtonen, E Hyvönen, M E Ristola, M Fogarty, C L Tienari, J Lassenius, M I Forsblom, C Lehto, M Saleem, M A Groop, P-H Holthöfer, H Lehtonen, S Cell Death Dis Original Article High serum lipopolysaccharide (LPS) activity in normoalbuminuric patients with type 1 diabetes (T1D) predicts the progression of diabetic nephropathy (DN), but the mechanisms behind this remain unclear. We observed that treatment of cultured human podocytes with sera from normoalbuminuric T1D patients with high LPS activity downregulated 3-phosphoinositide-dependent kinase-1 (PDK1), an activator of the Akt cell survival pathway, and induced apoptosis. Knockdown of PDK1 in cultured human podocytes inhibited antiapoptotic Akt pathway, stimulated proapoptotic p38 MAPK pathway, and increased apoptosis demonstrating an antiapoptotic role for PDK1 in podocytes. Interestingly, PDK1 was downregulated in the glomeruli of diabetic rats and patients with type 2 diabetes before the onset of proteinuria, further suggesting that reduced expression of PDK1 associates with podocyte injury and development of DN. Treatment of podocytes in vitro and mice in vivo with LPS reduced PDK1 expression and induced apoptosis, which were prevented by inhibiting the Toll-like receptor (TLR) signaling pathway with the immunomodulatory agent GIT27. Our data show that LPS downregulates the cell survival factor PDK1 and induces podocyte apoptosis, and that blocking the TLR pathway with GIT27 may provide a non-nephrotoxic means to prevent the progression of DN. Nature Publishing Group 2015-05 2015-05-07 /pmc/articles/PMC4669704/ /pubmed/25950482 http://dx.doi.org/10.1038/cddis.2015.125 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Saurus, P Kuusela, S Lehtonen, E Hyvönen, M E Ristola, M Fogarty, C L Tienari, J Lassenius, M I Forsblom, C Lehto, M Saleem, M A Groop, P-H Holthöfer, H Lehtonen, S Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway |
title | Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway |
title_full | Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway |
title_fullStr | Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway |
title_full_unstemmed | Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway |
title_short | Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway |
title_sort | podocyte apoptosis is prevented by blocking the toll-like receptor pathway |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669704/ https://www.ncbi.nlm.nih.gov/pubmed/25950482 http://dx.doi.org/10.1038/cddis.2015.125 |
work_keys_str_mv | AT saurusp podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT kuuselas podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT lehtonene podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT hyvonenme podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT ristolam podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT fogartycl podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT tienarij podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT lasseniusmi podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT forsblomc podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT lehtom podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT saleemma podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT groopph podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT holthoferh podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway AT lehtonens podocyteapoptosisispreventedbyblockingthetolllikereceptorpathway |